JANX Valuation

Janux Therapeutics Inc

Add to Watchlist

Advanced Chart

28.710

+0.2(0.702%)1D

JANX Relative Valuation

JANX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, JANX is overvalued; if below, it's undervalued.

Historical Valuation

Janux Therapeutics Inc (JANX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 28.71 is considered Undervalued compared with the five-year average of -15.68. The fair price of Janux Therapeutics Inc (JANX) is between 43.56 to 701.06 according to relative valuation methord. Compared to the current price of 28.71 USD , Janux Therapeutics Inc is Undervalued By 34.09%.

Relative Value

Fair Zone

43.56-701.06

Current Price：28.71

34.09%

Undervalued

-9.67

Trailing

Forward

-3.90

EV/EBITDA

Janux Therapeutics Inc. (JANX) has a current EV/EBITDA of -3.90. The 5-year average EV/EBITDA is -8.39. The thresholds are as follows: Strongly Undervalued below -25.90, Undervalued between -25.90 and -17.15, Fairly Valued between 0.36 and -17.15, Overvalued between 0.36 and 9.12, and Strongly Overvalued above 9.12. The current Forward EV/EBITDA of -3.90 falls within the Historic Trend Line -Fairly Valued range.

-3.82

EV/EBIT

Janux Therapeutics Inc. (JANX) has a current EV/EBIT of -3.82. The 5-year average EV/EBIT is -8.76. The thresholds are as follows: Strongly Undervalued below -26.89, Undervalued between -26.89 and -17.83, Fairly Valued between 0.30 and -17.83, Overvalued between 0.30 and 9.36, and Strongly Overvalued above 9.36. The current Forward EV/EBIT of -3.82 falls within the Historic Trend Line -Fairly Valued range.

28.71

Janux Therapeutics Inc. (JANX) has a current PS of 28.71. The 5-year average PS is 461.45. The thresholds are as follows: Strongly Undervalued below -360.42, Undervalued between -360.42 and 50.52, Fairly Valued between 872.38 and 50.52, Overvalued between 872.38 and 1283.32, and Strongly Overvalued above 1283.32. The current Forward PS of 28.71 falls within the Undervalued range.

-17.13

P/OCF

Janux Therapeutics Inc. (JANX) has a current P/OCF of -17.13. The 5-year average P/OCF is -14.32. The thresholds are as follows: Strongly Undervalued below -54.89, Undervalued between -54.89 and -34.60, Fairly Valued between 5.96 and -34.60, Overvalued between 5.96 and 26.25, and Strongly Overvalued above 26.25. The current Forward P/OCF of -17.13 falls within the Historic Trend Line -Fairly Valued range.

-9.66

P/FCF

Janux Therapeutics Inc. (JANX) has a current P/FCF of -9.66. The 5-year average P/FCF is -15.82. The thresholds are as follows: Strongly Undervalued below -41.19, Undervalued between -41.19 and -28.51, Fairly Valued between -3.14 and -28.51, Overvalued between -3.14 and 9.54, and Strongly Overvalued above 9.54. The current Forward P/FCF of -9.66 falls within the Historic Trend Line -Fairly Valued range.

Janux Therapeutics Inc (JANX) has a current Price-to-Book (P/B) ratio of 1.72. Compared to its 3-year average P/B ratio of 2.38 , the current P/B ratio is approximately -27.65% higher. Relative to its 5-year average P/B ratio of 2.22, the current P/B ratio is about -22.48% higher. Janux Therapeutics Inc (JANX) has a Forward Free Cash Flow (FCF) yield of approximately -3.52%. Compared to its 3-year average FCF yield of -6.04%, the current FCF yield is approximately -41.75% lower. Relative to its 5-year average FCF yield of -5.31% , the current FCF yield is about -33.75% lower.

1.72

P/B

Median3y

2.38

Median5y

2.22

-3.52

FCF Yield

Median3y

-6.04

Median5y

-5.31

Competitors Valuation Multiple

The average P/S ratio for JANX's competitors is 13.69, providing a benchmark for relative valuation. Janux Therapeutics Inc Corp (JANX) exhibits a P/S ratio of 28.71, which is 109.74% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

JANX.O

Janux Therapeutics Inc

Xeris Biopharma Holdings Inc

BioCryst Pharmaceuticals Inc

Sana Biotechnology Inc

4.95

1.22B

AUPH.O

Aurinia Pharmaceuticals Inc

Edgewise Therapeutics Inc

18.28

1.93B

Performance Decomposition

Market capitalization of JANX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of JANX in the past 1 year is driven by Unknown.